Super-resolution Ultrasound Imaging for Chronic Kidney Disease
Trial Summary
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Lumason for chronic kidney disease?
Research shows that microbubbles based on sulfur hexafluoride, like those in Lumason, have been developed to enhance ultrasound imaging, which can improve the visibility of organs like the liver and kidney. This suggests that Lumason may help in better imaging of the kidneys in chronic kidney disease.12345
Is Lumason safe for use in humans?
Lumason, an ultrasound contrast agent, is generally safe for use in humans, including special populations and critically ill patients. Serious allergic reactions are rare, but healthcare providers should be prepared for them. Post-marketing data over 20 years show very low rates of adverse events.678910
What makes Lumason unique for treating chronic kidney disease?
What is the purpose of this trial?
The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.
Research Team
Shigao Chen, PhD
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for healthy volunteers or patients with Chronic Kidney Disease who need a kidney biopsy. It's not open to those unable to consent, prisoners, pregnant or nursing women, people allergic to ultrasound contrast agents, or patients with serious heart conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent to evaluate renal microvessel characteristics
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- Lumason
Lumason is already approved in United States for the following indications:
- Echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
- Ultrasonography of the liver to characterize focal liver lesions in adult and pediatric patients
- Ultrasonography of the urinary tract for the evaluation of suspected or unknown vesicoureteral reflux in pediatric patients
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator